COYA

Coya Therapeutics Inc

4.18

Oct 14 • 3:59 PM ET -0.30 (-6.59%)

4.26

Aftermarket • 7:30 PM ET +0.08 (1.91%)

Healthcare Biotechnology USA Micro NASD

Today, 8:10 AMCoya Therapeutics to launch COYA 302 ALS Phase 2/3 ALSTARS extension, delays frontotemporal dementia trial start to 2027

Peers: ANIX CYPH INO LONA NRXS ATYR CGTX KLRS NRXP KALA

| Held by: VTI VXF DFAS IWC DFMC AVSC DXUV DFAC DCOR DFSU

Scroll to Statements

Index	-
Market Cap	98.05M
Enterprise Value	54.87M
Income	-21.67M
Sales	8.02M
Book/sh	1.84
Cash/sh	1.84
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8
IPO	Dec 29, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	12.23
P/B	2.27
P/C	2.27
P/FCF	-
EV/EBITDA	-
EV/Sales	6.84
Quick Ratio	13.40
Current Ratio	13.40
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.00
EPS next Y	-1.43
EPS next Q	-0.34
EPS this Y	-4.39%
EPS next Y	-7.99%
EPS next 5Y	5.40%
EPS past 3/5Y	-1.01% -75.69%
Sales past 3/5Y	- -
EPS Y/Y TTM	19.33%
Sales Y/Y TTM	1793.76%
EPS Q/Q	22.34%
Sales Q/Q	48.97%
Earnings	Aug 11 BMO
EPS/Sales Surpr.	19.00% 45.08%

Insider Own	14.69%
Insider Trans	0.00%
Inst Own	33.21%
Inst Trans	-1.79%
ROA	-53.66%
ROE	-60.54%
ROIC	-50.07%
Gross Margin	99.76%
Oper. Margin	-260.00%
Profit Margin	-270.22%
SMA20	-14.50%
SMA50	-12.40%
SMA200	-11.24%
Trades

Shs Outstand	23.46M
Shs Float	20.01M
Short Float	5.95%
Short Ratio	7.92
Short Interest	1.19M
52W High	7.75 -46.06%
52W Low	3.71 12.67%
Volatility	7.41% 5.87%
ATR (14)	0.28
RSI (14)	33.25
Beta	0.57
Rel Volume	1.71
Avg Volume	150.50K
Volume	258,003

Perf Week	-14.87%
Perf Month	-10.11%
Perf Quarter	-9.13%
Perf Half Y	-7.73%
Perf YTD	-27.93%
Perf Year	-41.94%
Perf 3Y	-16.40%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	15.21
Prev Close	4.47
Price	4.18
Change %	-6.59%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-26	Initiated	Roth Capital	Buy	$12
Jul-09-25	Initiated	Lake Street	Buy	$16
Dec-04-24	Initiated	D. Boral Capital	Buy	$15

Today 08:00AM	Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS (Business Wire) -6.59%
Oct-13-26 08:00AM	Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference (Business Wire) -6.96%
Oct-05-26 08:00AM	Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS (Business Wire)
Sep-15-26 08:00AM	Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS (Business Wire)
Sep-08-26 08:00AM	Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation (Business Wire)
08:00AM	Loading…
Aug-11-26 08:00AM	Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update (Business Wire)
Jun-18-26 08:00AM	Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting (Business Wire)
Jun-15-26 08:00AM	Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease (Business Wire)
Jun-08-26 08:00AM	Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase (Business Wire)
May-27-26 08:00AM	Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit (Business Wire)
May-14-26 07:15AM	Coya Therapeutics secures FDA fast track status for COYA 302 (Pharmaceutical Technology) +15.86%
May-12-26 08:35AM	Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs (Exec Edge)
07:35AM	Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update (Business Wire)
07:30AM	Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) (Business Wire)
May-07-26 08:35AM	NanoViricides to Participate at D. Boral Capital Global Conference in NYC (Exec Edge)
08:35AM	Loading…
May-06-26 08:35AM	NanoViricides Measles Treatment Granted Orphan Drug Designation by FDA (Exec Edge)
Apr-09-26 08:00AM	Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS (Business Wire) +10.22%
Apr-02-26 08:00AM	Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director (Business Wire)
Mar-18-26 08:00AM	Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy (Business Wire)
Mar-16-26 08:00AM	Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results (Business Wire)
Feb-25-26 12:00PM	Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Feb-17-26 04:35PM	Coya Therapeutics Details ALS Combo Immunotherapy Plan, Highlights Early Biomarker Signals in Webinar (MarketBeat)
Feb-10-26 08:00AM	Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial (Business Wire)
Jan-31-26 08:15AM	Coya Therapeutics to sell 2.522M shares at $4.40 in private placement (TipRanks)
Jan-30-26 08:00AM	Coya Therapeutics Announces $11.1 Million Private Placement (Business Wire)
Jan-20-26 08:00AM	Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders (Business Wire)
Jan-08-26 08:00AM	Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients (Business Wire)
Dec-23-25 08:00AM	Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) (Business Wire)
Dec-09-25 08:00AM	Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS (Business Wire)
Dec-02-25 04:46PM	ReAlta Life Sciences Designates Dr. Howard Berman as Executive Chairman (Exec Edge)
08:00AM	Loading…
Nov-25-25 08:00AM	Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences (Business Wire)
Nov-12-25 08:00AM	Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update (Business Wire)
Nov-04-25 08:00AM	Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo (Business Wire)
Oct-28-25 07:41AM	Here's Greenlight Capital's Update on Coya Therapeutics (COYA) (Insider Monkey)
Oct-27-25 04:01PM	Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire)
Oct-24-25 06:30AM	Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock (Business Wire) -9.74%
Oct-23-25 04:31PM	Coya Therapeutics Announces Proposed Public Offering of Common Stock (Business Wire) -5.16%
Oct-07-25 08:00AM	Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function (Business Wire)
Sep-29-25 08:00AM	Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia (PR Newswire)
Sep-22-25 08:00AM	Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis (PR Newswire)
Sep-16-25 08:00AM	Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model (PR Newswire)
07:45AM	EXCLUSIVE: Coya Therapeutics Investigational Combination Therapy With GLP-1 Shows Potential For Alzheimer's Disease (Benzinga)
Sep-04-25 08:00AM	Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial (PR Newswire)
Sep-03-25 08:34AM	Coya Therapeutics to Participate at Upcoming September Investor Conferences (PR Newswire)
Aug-27-25 09:55AM	Coya Therapeutics, Inc. (COYA) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Aug-26-25 05:38AM	FDA approves Coya Therapeutics trial of COYA 302 for ALS (Clinical Trials Arena)
Aug-12-25 03:00PM	Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update (PR Newswire)
Aug-07-25 08:20AM	Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-06-25 08:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-25-25 09:56AM	Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains? (Zacks)
Jul-24-25 08:15AM	Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease (Business Wire) +10.71%
Jul-22-25 08:15AM	Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 - 30, 2025 (Business Wire)
Jun-18-25 08:15AM	Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 - 25, 2025 (Business Wire)
Jun-02-25 08:00AM	Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations (Business Wire)
May-16-25 10:53AM	Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference (Business Wire)
May-13-25 08:00AM	Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update (Business Wire) -6.19%
May-08-25 08:15AM	Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025 (Business Wire)
Apr-29-25 09:40AM	Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-25-25 11:27AM	Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release (Seeking Alpha) -5.36%
Apr-24-25 08:00AM	Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia (ACCESSWIRE)
Apr-23-25 09:55AM	Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High? (Zacks)
Apr-21-25 09:51AM	Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) (Business Wire) +8.56%
Apr-17-25 07:00AM	Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program (GlobeNewswire)
Apr-11-25 03:02PM	Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
Apr-01-25 08:15AM	Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 (Business Wire)
Mar-27-25 12:00PM	What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock (Zacks) +5.84%
09:55AM	Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet (Zacks)
09:40AM	Are Medical Stocks Lagging Auna S.A. (AUNA) This Year? (Zacks)
Mar-26-25 08:15AM	Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program (Business Wire)
08:00AM	The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors (Business Wire)
Mar-18-25 08:15AM	Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results (Business Wire) -5.84%
Feb-25-25 08:15AM	Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations (Business Wire)
Feb-06-25 01:30PM	Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing (Benzinga) +7.20%
08:00AM	Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimers Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development (Business Wire)
Feb-04-25 08:15AM	Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-27-25 02:54AM	An ALS treatment wave is approaching, and this biotech CEO is ready to surf (Pharma Voice)
Jan-21-25 08:15AM	Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases (Business Wire) +5.20%
08:00AM	EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases (Benzinga)
Dec-18-24 08:15AM	Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD) (Business Wire) -7.13%
Nov-25-24 08:15AM	Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference (Business Wire)
Nov-19-24 08:15AM	Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders (Business Wire)
Nov-06-24 08:00AM	Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results (Business Wire) +7.72%
Nov-01-24 08:15AM	Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer (Business Wire)
Oct-30-24 08:29AM	Coya Therapeutics Reports Positive Phase 2 Alzheimers Trial Results (TipRanks) -9.70%
Oct-29-24 02:36PM	Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study (Benzinga) -27.67%
06:30AM	Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain) (Business Wire)
Oct-28-24 08:00AM	Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimers Disease (Business Wire) +13.73%
Oct-23-24 04:05PM	Coya Therapeutics Announces Closing of $10.0 Million Private Placement (Business Wire)
Oct-22-24 09:00AM	Coya Therapeutics Announces $10.0 Million Private Placement (Business Wire) +16.44%
Oct-08-24 09:15AM	Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100 (Business Wire)
Sep-24-24 08:15AM	Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference (Business Wire)
Sep-16-24 08:15AM	Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson's Disease (Business Wire)
Sep-03-24 08:15AM	Coya Therapeutics to Present at Upcoming Healthcare Conferences (Business Wire)
Aug-19-24 09:00AM	Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024 (Business Wire) +9.77%
Aug-12-24 08:00AM	Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results (Business Wire) -12.87%
Aug-02-24 08:15AM	Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Business Wire) -6.53%
Jul-31-24 08:15AM	Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (Business Wire)
Jun-20-24 08:15AM	Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic (Business Wire)
Jun-11-24 08:15AM	Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology (Business Wire) +12.68%

Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing proprietary new therapies to enhance the function of regulatory T cells. Its pipeline includes Treg Modifying Biologics, Allogeneic Treg-Derived Exosomes, and Autologous Treg Cell Therapy. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.

CEO & DirectorDr. Arun Swaminathan Ph.D.

FAPADr. Fred Grossman D.O.

CFO & COOMr. David S. Snyder M.B.A.

Head of Neuroinflammation PlatformMr. Aaron Thome Ph.D.

Senior Vice President of RegulatoryDr. Michelle Frazier Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

COYA

Coya Therapeutics Inc

Upgrade your Finviz experience